300871SZSE

Hui Sheng Biotechnology Co., Ltd.

回盛生物

300871

Shenzhen Stock Exchange

Follow
47 announcements tracked· Last: May 22, 2026

Key Financials

Revenue¥458.2M
Net Profit¥77.7M
ROE3.45%
Debt Ratio30.18%
Monetary Funds¥398.3M
Receivables¥442.1M
Goodwill¥522K
Total Shares201.8M

Announcements

47 total

Announcement on the Shenzhen Stock Exchange's Decision to Terminate Review of Company's Stock Issuance Application

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on the Completion of Registration Capital and Business Scope Change Registration and Reissuance of Business License

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Legal Opinion Letter from Guohao Law Firm (Shenzhen) Regarding the 2025 Annual Shareholders' Meeting of Wuhan Huisheng Biotechnology Co., Ltd.

Share PledgeShareholding Change DisclosureCapital Reduction

Announcement of Resolutions from the 2025 Annual Shareholders' Meeting

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement of Resolutions of the Seventh Meeting of the Fourth Board of Directors

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

2026 First Quarter Report

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on the expiration of the plan to issue A-shares to specific objects for the year 2024

Share Repurchase PlanShareholding Change DisclosureCapital Reduction

Legal Opinion from Guohao Law Firm (Shenzhen) on the Second Extraordinary General Meeting of Shareholders of Wuhan Huisheng Biotechnology Co., Ltd. in 2026

Share PledgeShareholding Change DisclosureCapital Reduction

Announcement of Resolutions from the Second Extraordinary General Meeting of Shareholders in 2026

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on the Reappointment of the Audit Institution for the Year 2026

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on Confirming the Remuneration for Directors and Senior Management for the Year 2025 and the Remuneration Plan for 2026

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Board of Directors Work Report for the Year 2025

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Independent Director's Work Report for the Year 2025 (Cai Xuepeng, Resigned)

Convertible BondsShareholding Change DisclosureCapital Reduction

Independent Director's Work Report for the Year 2025 (Wang Ming)

Convertible BondsShareholding Change DisclosureCapital Reduction

Independent Director's Work Report for the Year 2025 (Ran Mingdong)

Convertible BondsShareholding Change DisclosureCapital Reduction

Announcement on Holding the Online Performance Briefing for the Year 2025

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Internal Control Audit Report for the Year 2025

Share PledgeShareholding Change DisclosureCapital Reduction

Internal Control Evaluation Report for Wuhan Huisheng Biotechnology Co., Ltd. for the Year 2025

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Remuneration Management Measures for Directors and Senior Management (April 2026)

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on Increasing the Guarantee Limit for Wholly-owned Subsidiaries

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Notice of the Annual Shareholders' Meeting for the Year 2025

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement of Resolutions from the Sixth Meeting of the Fourth Board of Directors

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on the Profit Distribution Plan for 2025 and the Mid-term Dividend Plan for 2026

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Special Report from the Board of Directors on the Storage, Management, and Use of Funds Raised for the Year 2025

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Verification Report on the Annual Storage, Management, and Use of Funds Raised by Wuhan Huisheng Biotechnology Co., Ltd.

Share Repurchase CompletionShare PledgeShareholding Change Disclosure

CITIC Construction Investment Securities Co., Ltd. Special Verification Report on the Storage, Management, and Use of Funds Raised by Wuhan Huisheng Biotechnology Co., Ltd. for the Year 2025

Share Repurchase CompletionShareholder Share IncreaseShare Pledge

Evaluation Report on the Performance of the Accounting Firm for the Year 2025

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Report of the Audit Committee on the Performance of Supervisory Duties by the Accounting Firm

Share Repurchase PlanShareholding Change DisclosureCapital Reduction

Special Audit Report on the Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions by Wuhan Huisheng Biotechnology Co., Ltd.

Share Repurchase CompletionShare PledgeShareholding Change Disclosure

Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions for the Year 2025 by Wuhan Huisheng Biotechnology Co., Ltd.

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Special Opinion of the Board on the Independence of Independent Directors

Share Repurchase CompletionConvertible BondsShareholding Change Disclosure

2025 Annual Audit Report

Share PledgeShareholding Change DisclosureCapital Reduction

2025 Annual Report

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Summary of the 2025 Annual Report

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on Extending the Validity Period of the Shareholders' Meeting Resolution for the Company's 2024 A-share Issuance to Specific Objects and Related Authorizations

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Progress Announcement on Providing Guarantees for Subsidiaries

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Notice of the 2026 Second Extraordinary Shareholders' Meeting

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Resolution Announcement of the 5th Meeting of the 4th Board of Directors

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on the Completion of Cancellation of Repurchased Shares and Share Changes

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Progress Announcement on Providing Guarantees for Subsidiaries

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Resolution announcement of the first meeting of all holders of the 2026 employee stock ownership plan

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on the completion of non-transactional transfer of the 2026 employee stock ownership plan

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on Cancelling Part of Repurchased Shares to Reduce Registered Capital and Notifying Creditors

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Articles of Association (Revised in February 2026)

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Grandall Law Firm (Shenzhen) Legal Opinion on Wuhan Huishang Biotechnology Co., Ltd.'s First Extraordinary General Meeting in 2026

Share PledgeShareholding Change DisclosureCapital Reduction

Resolution Announcement of the First Extraordinary General Meeting in 2026

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on Receiving Government Subsidies

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Notes & Comments

Sign in to leave a comment or private note.

Loading…